Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation

Melissa B. King-Biggs, Jordan M. Dunitz, Soon J. Park, S. Kay Savik, Marshall I. Hertz

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Goal. The goal of this study was to assess the efficacy of sirolimus in lung-transplant recipients. Methods. The study was designed as a single center, consecutive case study of lung-transplant recipients treated with sirolimus, tacrolimus, and prednisone. All study subjects also received an HMG-CoA reductase inhibitor, and prophylaxis for cytomegalovirus and Pneumocystis carinii. Results. A total of 15 subjects were enrolled in the study. Within 6 months, significant airway complications occurred in four subjects, three of whom died. At that point, the investigators terminated enrollment in the study. The study population was compared retrospectively with a group of 83 consecutive lung recipients treated with cyclosporine (n=64) or tacrolimus (n=19), mycophenolate mofetil, and prednisone. This confirmed an increased incidence of airway dehiscence and reduced survival in the sirolimus-treated patients. Sirolimus-treated patients had a low incidence of acute rejection. No significant differences were noted in the incidence of bacterial or fungal bronchopulmonary infections. Conclusions. We observed an unexpectedly high incidence of postoperative airway dehiscence in lung-transplant recipients treated with sirolimus, in combination with tacrolimus, prednisone, and an HMG-CoA inhibitor. Further studies will be needed to determine the safety and efficacy of using sirolimus after complete airway healing has occurred.

Original languageEnglish (US)
Pages (from-to)1437-1443
Number of pages7
JournalTransplantation
Volume75
Issue number9
DOIs
StatePublished - May 15 2003
Externally publishedYes

Fingerprint

Lung Transplantation
Sirolimus
Tacrolimus
Prednisone
Lung
Incidence
Mycophenolic Acid
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pneumocystis carinii
Mycoses
Cytomegalovirus
Cyclosporine
Research Personnel
Safety
Survival
Population
Transplant Recipients

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. / King-Biggs, Melissa B.; Dunitz, Jordan M.; Park, Soon J.; Savik, S. Kay; Hertz, Marshall I.

In: Transplantation, Vol. 75, No. 9, 15.05.2003, p. 1437-1443.

Research output: Contribution to journalArticle

King-Biggs, Melissa B. ; Dunitz, Jordan M. ; Park, Soon J. ; Savik, S. Kay ; Hertz, Marshall I. / Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. In: Transplantation. 2003 ; Vol. 75, No. 9. pp. 1437-1443.
@article{e305b28a893f49159d53f0348ade31ca,
title = "Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation",
abstract = "Goal. The goal of this study was to assess the efficacy of sirolimus in lung-transplant recipients. Methods. The study was designed as a single center, consecutive case study of lung-transplant recipients treated with sirolimus, tacrolimus, and prednisone. All study subjects also received an HMG-CoA reductase inhibitor, and prophylaxis for cytomegalovirus and Pneumocystis carinii. Results. A total of 15 subjects were enrolled in the study. Within 6 months, significant airway complications occurred in four subjects, three of whom died. At that point, the investigators terminated enrollment in the study. The study population was compared retrospectively with a group of 83 consecutive lung recipients treated with cyclosporine (n=64) or tacrolimus (n=19), mycophenolate mofetil, and prednisone. This confirmed an increased incidence of airway dehiscence and reduced survival in the sirolimus-treated patients. Sirolimus-treated patients had a low incidence of acute rejection. No significant differences were noted in the incidence of bacterial or fungal bronchopulmonary infections. Conclusions. We observed an unexpectedly high incidence of postoperative airway dehiscence in lung-transplant recipients treated with sirolimus, in combination with tacrolimus, prednisone, and an HMG-CoA inhibitor. Further studies will be needed to determine the safety and efficacy of using sirolimus after complete airway healing has occurred.",
author = "King-Biggs, {Melissa B.} and Dunitz, {Jordan M.} and Park, {Soon J.} and Savik, {S. Kay} and Hertz, {Marshall I.}",
year = "2003",
month = "5",
day = "15",
doi = "10.1097/01.TP.0000064083.02120.2C",
language = "English (US)",
volume = "75",
pages = "1437--1443",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation

AU - King-Biggs, Melissa B.

AU - Dunitz, Jordan M.

AU - Park, Soon J.

AU - Savik, S. Kay

AU - Hertz, Marshall I.

PY - 2003/5/15

Y1 - 2003/5/15

N2 - Goal. The goal of this study was to assess the efficacy of sirolimus in lung-transplant recipients. Methods. The study was designed as a single center, consecutive case study of lung-transplant recipients treated with sirolimus, tacrolimus, and prednisone. All study subjects also received an HMG-CoA reductase inhibitor, and prophylaxis for cytomegalovirus and Pneumocystis carinii. Results. A total of 15 subjects were enrolled in the study. Within 6 months, significant airway complications occurred in four subjects, three of whom died. At that point, the investigators terminated enrollment in the study. The study population was compared retrospectively with a group of 83 consecutive lung recipients treated with cyclosporine (n=64) or tacrolimus (n=19), mycophenolate mofetil, and prednisone. This confirmed an increased incidence of airway dehiscence and reduced survival in the sirolimus-treated patients. Sirolimus-treated patients had a low incidence of acute rejection. No significant differences were noted in the incidence of bacterial or fungal bronchopulmonary infections. Conclusions. We observed an unexpectedly high incidence of postoperative airway dehiscence in lung-transplant recipients treated with sirolimus, in combination with tacrolimus, prednisone, and an HMG-CoA inhibitor. Further studies will be needed to determine the safety and efficacy of using sirolimus after complete airway healing has occurred.

AB - Goal. The goal of this study was to assess the efficacy of sirolimus in lung-transplant recipients. Methods. The study was designed as a single center, consecutive case study of lung-transplant recipients treated with sirolimus, tacrolimus, and prednisone. All study subjects also received an HMG-CoA reductase inhibitor, and prophylaxis for cytomegalovirus and Pneumocystis carinii. Results. A total of 15 subjects were enrolled in the study. Within 6 months, significant airway complications occurred in four subjects, three of whom died. At that point, the investigators terminated enrollment in the study. The study population was compared retrospectively with a group of 83 consecutive lung recipients treated with cyclosporine (n=64) or tacrolimus (n=19), mycophenolate mofetil, and prednisone. This confirmed an increased incidence of airway dehiscence and reduced survival in the sirolimus-treated patients. Sirolimus-treated patients had a low incidence of acute rejection. No significant differences were noted in the incidence of bacterial or fungal bronchopulmonary infections. Conclusions. We observed an unexpectedly high incidence of postoperative airway dehiscence in lung-transplant recipients treated with sirolimus, in combination with tacrolimus, prednisone, and an HMG-CoA inhibitor. Further studies will be needed to determine the safety and efficacy of using sirolimus after complete airway healing has occurred.

UR - http://www.scopus.com/inward/record.url?scp=0038586466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038586466&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000064083.02120.2C

DO - 10.1097/01.TP.0000064083.02120.2C

M3 - Article

C2 - 12792493

AN - SCOPUS:0038586466

VL - 75

SP - 1437

EP - 1443

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 9

ER -